These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18177758)

  • 1. Antipsychotic drugs for aggression in intellectual disability.
    Matson JL; Wilkins J
    Lancet; 2008 Jan; 371(9606):9-10. PubMed ID: 18177758
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
    Tyrer P; Oliver-Africano PC; Ahmed Z; Bouras N; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; North B; Eliahoo J; Karatela S; Soni A; Crawford M
    Lancet; 2008 Jan; 371(9606):57-63. PubMed ID: 18177776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
    Tyrer P; Oliver-Africano P; Romeo R; Knapp M; Dickens S; Bouras N; Ahmed Z; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; Karatela S; Lenôtre L; Watson J; Soni A; Crawford M; Eliahoo J; North B
    Health Technol Assess; 2009 Apr; 13(21):iii-iv, ix-xi, 1-54. PubMed ID: 19397849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
    Prescrire Int; 2009 Dec; 18(104):248. PubMed ID: 20025088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
    Romeo R; Knapp M; Tyrer P; Crawford M; Oliver-Africano P
    J Intellect Disabil Res; 2009 Jul; 53(7):633-43. PubMed ID: 19460067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics in individuals with intellectual disability.
    Trollor JN; Somerville ER; Somerville HM
    Lancet; 2008 May; 371(9623):1501; author reply 1502. PubMed ID: 18456092
    [No Abstract]   [Full Text] [Related]  

  • 7. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities.
    Oliver-Africano P; Dickens S; Ahmed Z; Bouras N; Cooray S; Deb S; Knapp M; Hare M; Meade M; Reece B; Bhaumik S; Harley D; Piachaud J; Regan A; Ade Thomas D; Karatela S; Rao B; Dzendrowskyj T; Lenôtre L; Watson J; Tyrer P
    J Intellect Disabil Res; 2010 Jan; 54(1):17-25. PubMed ID: 19627427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone for aggression and self-injurious behavior in adults with mental retardation.
    Cohen SA; Ihrig K; Lott RS; Kerrick JM
    J Autism Dev Disord; 1998 Jun; 28(3):229-33. PubMed ID: 9656134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic drugs in children with autism.
    Morgan S; Taylor E
    BMJ; 2007 May; 334(7603):1069-70. PubMed ID: 17525405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can risperidone be antidepressive and also inhibit aggression?
    Bernhard R
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):627-8. PubMed ID: 9447511
    [No Abstract]   [Full Text] [Related]  

  • 11. Atypical antipsychotic medications in the psychiatric emergency service.
    Currier GW
    J Clin Psychiatry; 2000; 61 Suppl 14():21-6. PubMed ID: 11154013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggression and schizophrenia: efficacy of risperidone.
    Buckley PF; Ibrahim ZY; Singer B; Orr B; Donenwirth K; Brar PS
    J Am Acad Psychiatry Law; 1997; 25(2):173-81. PubMed ID: 9213289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
    Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
    J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of relapse in schizophrenia.
    Curtin F
    N Engl J Med; 2002 May; 346(18):1412-3; author reply 1412-3. PubMed ID: 11986420
    [No Abstract]   [Full Text] [Related]  

  • 15. An importance of dose in antipsychotic combination therapy for schizophrenia.
    Suzuki T
    J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of relapse in schizophrenia.
    Geddes J
    N Engl J Med; 2002 Jan; 346(1):56-8. PubMed ID: 11778005
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
    Onalaja D; Jainer AK
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1076-7; author reply 1077. PubMed ID: 12404659
    [No Abstract]   [Full Text] [Related]  

  • 18. Not just another antipsychotic-for-conduct-problems trial.
    Blader JC
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):17-20. PubMed ID: 24342382
    [No Abstract]   [Full Text] [Related]  

  • 19. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.
    Yoshida K; Higuchi H; Hishikawa Y
    Clin Neuropharmacol; 1998; 21(1):68-9. PubMed ID: 9579290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptics for behavioral symptoms of dementia.
    Reynolds PL; Strayer SM
    J Fam Pract; 2000 Jan; 49(1):78-9. PubMed ID: 10678345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.